Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata

Recognition reinforces baricitinib's potential to be the first FDA-approved medicine for individuals living with alopecia areata INDIANAPOLIS, March 16, 2020 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) and Incyte Corp... Biopharmaceuticals, FDA Eli Lilly, baricitinib, alopecia areata
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news